COR
Cencora·NYSE
--
--(--)
--
--(--)
COR fundamentals
Cencora (COR) released its earnings on Feb 4, 2026: revenue was 85.90B (YoY +5.42%), missed estimates; EPS was 4.08 (YoY +9.38%), beat estimates.
Revenue / YoY
85.90B
+5.42%
EPS / YoY
4.08
+9.38%
Report date
Feb 4, 2026
COR Earnings Call Summary for Q1,2026
- OneOncology Acquisition Boosts Guidance: U.S. Healthcare Solutions operating income growth raised to 14%-16% YoY, driven by MSO expansion.
- Strong Q1 Financials: Adjusted EPS $4.08 (+9%), revenue $85.9B (+5.5%), with U.S. segment operating income up 21%.
- MSO Strategic Impact: OneOncology and RCA enable clinical research leadership, revenue cycle efficiency, and advanced treatment access.
- International Recovery: Global Specialty Logistics volumes growing, offsetting European distribution timing challenges.
- Capital Allocation Focus: Debt paydown prioritized, with long-term plans for strategic M&A and dividend growth.
EPS
Actual | 2.4 | 1.85 | 1.89 | 2.18 | 2.53 | 2.16 | 2.39 | 2.58 | 3.22 | 2.62 | 2.6 | 2.71 | 3.5 | 2.92 | 2.86 | 3.28 | 3.8 | 3.34 | 3.34 | 3.73 | 4.42 | 4 | 3.84 | 4.08 | ||||||||||||||||
Forecast | 2.2657 | 1.5802 | 1.8512 | 1.9459 | 2.481 | 2.0354 | 2.3572 | 2.5756 | 2.925 | 2.5643 | 2.5703 | 2.6384 | 3.2973 | 2.8194 | 2.8067 | 2.8959 | 3.6943 | 3.217 | 3.2265 | 3.5022 | 4.1148 | 3.8477 | 3.7866 | 4.0488 | ||||||||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +5.93% | +17.07% | +2.10% | +12.03% | +1.98% | +6.12% | +1.39% | +0.17% | +10.09% | +2.17% | +1.16% | +2.71% | +6.15% | +3.57% | +1.90% | +13.26% | +2.86% | +3.82% | +3.52% | +6.50% | +7.42% | +3.96% | +1.41% | +0.77% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 47.40B | 45.37B | 49.24B | 52.52B | 49.20B | 53.41B | 58.91B | 59.63B | 57.72B | 60.06B | 61.17B | 62.85B | 63.46B | 66.95B | 68.92B | 72.25B | 68.40B | 74.24B | 79.05B | 81.49B | 75.50B | 80.66B | 83.73B | 85.90B |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 45.94B | 44.64B | 48.06B | 50.51B | 49.98B | 52.16B | 57.17B | 59.60B | 57.48B | 59.08B | 60.54B | 62.81B | 60.46B | 63.93B | 66.25B | 69.25B | 70.60B | 73.32B | 77.62B | 78.31B | 75.68B | 80.09B | 83.46B | 86.06B |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +3.17% | +1.63% | +2.46% | +3.97% | -1.56% | +2.38% | +3.04% | +0.05% | +0.41% | +1.67% | +1.05% | +0.06% | +4.96% | +4.72% | +4.03% | +4.33% | -3.11% | +1.26% | +1.84% | +4.06% | -0.24% | +0.71% | +0.32% | -0.18% |
Earnings Call
You can ask Aime
What were the key takeaways from Cencora's earnings call?What factors drove the changes in Cencora's revenue and profit?What guidance did Cencora's management provide for the next earnings period?What is Cencora's gross profit margin?What is the market's earnings forecast for Cencora next quarter?What were the key takeaways from Cencora’s earnings call?What is the revenue and EPS growth rate for Cencora year over year?What is Cencora's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
